Latest Breaking News On - புத்திசாலி வளர்ச்சி செயல்பாட்டு ப்ரோக்ர்யாம் - Page 1 : comparemela.com
The Lubawa Group received a concession for the Research and Development Center
biznespolska.pl - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from biznespolska.pl Daily Mail and Mail on Sunday newspapers.
Almost PLN 70 million from European Funds to finance professional design process
wbj.pl - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from wbj.pl Daily Mail and Mail on Sunday newspapers.
Enea stores energy with the help of hydrogen
biznespolska.pl - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from biznespolska.pl Daily Mail and Mail on Sunday newspapers.
Even 300,000 PLN non-returnable grant for the development of economic activity in Poland
Even 300,000 PLN a non-returnable grant to get start-ups under the “Acceleration Programs – Poland Prize”. The Polish Agency for Enterprise Development has just selected new entities that will work with the originators and awarding funds for the implementation of young, perspective projects. The initiative is aimed exclusively at foreign start-ups.
The initiative is aimed at attracting interesting, innovative projects to the Vistula River, which from the initial phase, thanks to the aid from the program, will go out into the open with their products or services. The project is implemented with the funds of the Smart Growth Operational Program, and its budget is currently over PLN 100 million. What start-ups are the organizers’ target and what conditions must be met for the originator to be able to obtain support?
WPD Pharmaceuticals Inc. (CSE: WBIO)(FSE: 8SV1) (the “
Company” or “
WPD”) a clinical-stage pharmaceutical company, is pleased to announce that it has been conditionally awarded a grant of $6,730,036 (20,394,049.68 PLN) from the Polish National Center for Research and Development (“
NCRD”), for the development of Annamycin, the Company’s drug candidate used in the treatment of Acute Myeloid Leukemia (“
AML”).
Annamycin is a “next generation” anthracycline, that has been shown to be less cardiotoxic compared to other anthracycline, such as doxorubicin, and to avoid multidrug resistance, so the use of Annamycin may not face the same dose limitations imposed on doxorubicin. The project entitled: “A novel approach to the therapy of acute myeloid leukemia (AML)” will be co-financed by the European Union, from the European Regional Development Fund, under the Smart Growth Operational Program 2014-2020. The funds will be used on the continued development of An